Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Pharmacokinetics and radiation dose of oxygen-15 labelled butanol in rCBF studies in humans (1994)
    Springer
    European journal of nuclear medicine 21 (1994), S. 138-143 
    Details
    ISSN: 1619-7089
    Keywords: Oxygen-15 labelled butanol ; Pharmacokinetics ; Dosimetry ; Cerebral blood flow ; Positron emission tomography
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract In this positron emission tomography (PET) study in humans we determined the pharmacokinetics and radiation dose of oxygen-15 labelled butanol, a recently introduced tracer for regional cerebral blood flow (rCBF). This report includes a description of the automated preparation of 150-butanol which allows repetitive activation studies, each 15 min apart. Dynamic rCBF studies were extended by prolonged measurements up to 15 min after injection over different organs such as brain, liver, kidneys and bladder. All measurements were done with a whole-body PET camera PC4096-15WB. Based on the pharmacokinetic data in 13 subjects the radiation doses to single organs were calculated according to MIRD pamphlet No. 11 and the effective dose defined by ICRP 60 as an indicator of radiation dose to the total body. The liver received the highest radiation dose of about 2.2 mGy per 1500 MBq of injected 15O-butanol, which is the typical amount of administered tracer in one rCBF measurement. The dose to the kidneys was 1.6 mGy, to the stomach 0.8 mGy, and to the brain 0.16 mGy. The effective dose was 0.54 mGy, which was similar to that of H2 15O, but lower than the effective dose from C15O2 in amounts typically applied in human rCBF studies.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00175761
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer (1999)
    Springer
    European journal of nuclear medicine 26 (1999), S. 226-230 
    Details
    ISSN: 1619-7089
    Keywords: Key words: Breast cancer ; Fluorine-18 fluorodeoxyglucose ; Positron emission tomography ; Tumour-to-non-tumour ratio ; Contrast parameters
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract. Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) has proven useful in the differentiation of various tumour entities, including breast cancer. In patients with primary breast cancer we performed a 3-h imaging protocol to examine possible improvements in tumour detectability and image contrast. Twenty-nine patients with primary breast cancer with a diameter of ≥2 cm that was demonstrated to be malignant by biopsy or surgery were injected with 370–740 MBq 18F-FDG and scanned in the prone position. Data were acquired 0–40 min, 1.5 h and 3.0 h after injection. After correction for measured attenuation, decay and scatter and iterative reconstruction, standardised uptake values (SUVs) and tumour-to-non-tumour and tumour-to-organ ratios were calculated. Visual analysis was performed using transverse, sagittal and coronal slices as well as 3D reprojection images. Tumour-to-non-tumour and tumour-to-organ ratios were significantly higher for the 3-h images than for the 1.5-h images. SUVs did not increase to the same extent. Lesion detectability was 83% in 1.5-h images compared to 93% in 3-h images. We conclude that tumour contrast in breast cancer is improved by starting the PET acquisition at 3 h p.i. rather than at 1.5 h p.i.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002590050381
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Effect of partial volume correction on muscarinic cholinergic receptor imaging with single-photon emission tomography in patients with temporal lobe epilepsy (1997)
    Springer
    European journal of nuclear medicine 24 (1997), S. 1156-1161 
    Details
    ISSN: 1619-7089
    Keywords: Key words: Cholinergic system ; Muscarinic receptors ; Epilepsy ; Emission tomography
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract. Animal experiments and preliminary results in humans have indicated alterations of hippocampal muscarinic acetylcholine receptors (mAChR) in temporal lobe epilepsy. Patients with temporal lobe epilepsy often present with a reduction in hippocampal volume. The aim of this study was to investigate the influence of hippocampal atrophy on the quantification of mAChR with single photon emission tomography (SPET) in patients with temporal lobe epilepsy. Cerebral uptake of the muscarinic cholinergic antagonist [123I]4-iododexetimide (IDex) was investigated by SPET in patients suffering from temporal lobe epilepsy of unilateral (n=6) or predominantly unilateral (n=1) onset. Regions of interest were drawn on co-registered magnetic resonance images. Hippocampal volume was determined in these regions and was used to correct the SPET results for partial volume effects. A ratio of hippocampal IDex binding on the affected side to that on the unaffected side was used to detect changes in muscarinic cholinergic receptor density. Before partial volume correction a decrease in hippocampal IDex binding on the focus side was found in each patient. After partial volume no convincing differences remained. Our results indicate that the reduction in hippocampal IDex binding in patients with epilepsy is due to a decrease in hippocampal volume rather than to a decrease in receptor concentration.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01254249
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Whole-body kinetics and dosimetry of l-3-[123I]iodo-α-methyltyrosine (1997)
    Springer
    European journal of nuclear medicine 24 (1997), S. 1162-1166 
    Details
    ISSN: 1619-7089
    Keywords: Key words: l-3-[I-123]iodo-α-methyltyrosine ; Dosimetry ; Brain tumours ; Amino acids
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract. The synthetic amino acid l-3-[123I]iodo-α-methyltyrosine (IMT) is currently under clinical evaluation as a single-photon emission tomography (SPET) tracer of amino acid uptake in brain tumours. So far, dosimetric data in respect of IMT are not available. Therefore we investigated the whole-body distribution of IMT in six patients with cerebral gliomas and the radiation doses were estimated. Whole-body scans were acquired at 1.5, 3 and 5 h after i.v. injection of 370–550 MBq IMT. The bladder was voided prior to each scan and the radioactivity excreted in the urine was measured. Based on the MIRD-11 method and the updated MIRDOSE3, the mean absorbed doses for various organs and the effective dose were calculated from geometric means of the anterior and posterior whole-body scans using seven source organs and the residence time. IMT was predominantly excreted by the kidneys (52.8%±11.5% at 1.5 h p.i., 63.0%±15.7% at 3 h p.i. and 74.6%±9.8% at 5 h p.i.). No organ system other than the urinary tract showed significant retention of the tracer. Early whole-body scans revealed slightly increased tracer uptake in the liver and in the bowel. Highest absorbed doses were found for the urinary bladder wall (0.047 mGy/MBq), the kidneys (0.010 mGy/MBq), the lower large intestinal wall (0.011 mGy/MBq) and the upper large intestinal wall (0.008 mGy/MBq). The effective dose according to ICRP 60 was estimated to be 0.0073 mSv/MBq for adults. This leads to an effective dose of 3.65 mSv in a typical brain SPET study using 500 MBq IMT. The MIRDOSE3 scheme yielded similar results. Thus, in spite of the relatively high tracer dose required for optimal brain scanning, radiation exposure in SPET studies with IMT is in the normal range of routine nuclear medicine investigations.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01254250
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...